The Company’s corporate partnering strategy is to out-license our proprietary alphavaccine technology for specific disease and/or antigen applications for commercialization.
The alphavaccine technology is based on AlphaVax’s proprietary RNA
replicon vector platform derived from attenuated strains of the alphavirus, Venezuelan equine encephalitis (VEE) virus.
AlphaVax 's in-house focus is today on the commercial potential of its alphavaccine vector technology in cancer immunotherapy. External third party partners are working on anti-infective vaccines.
We are a privately-held, clinical-stage biopharmaceutical company, that has used its proprietary RNA particle alphavaccine vector platform technology to generate a portfolio of seven vaccine candidates for infectious disease prevention and cancer immunotherapy. Additional candidates for bio-defence applications have also been developed.
Four alphavaccine candidates, targeting human cytomegalovirus, influenza A virus, prostate cancer and HIV-1, have been evaluated in five Phase 1 clinical trials. More recently, AVX has focused its efforts in an additional three clinical trials with two additional vaccine candidates (one in breast cancer, two in GI cancers) in the development of immunotherapeutic vaccines for the treatment of various cancers. From these latter efforts, AVX has successfully progressed the development of its proprietary alphavaccine RNA particletechnology, to create new, potentially first-in-class, vaccines that engage the patient’s immune system both to recognize and fight off various cancers.
Results from AVX’s first trial evaluating its CEA alphavaccine in patients with Stage IV colon cancer showed the vector technology was able to “break self-tolerance” and a trend for enhanced survival in patients with CEA-specific T cell responses.
As a follow-up, AVX has completed clinical trials in breast cancer and gastrointestinal cancers (in Stage III patients).